Ropivacaine is a long-acting, enantiomerically pure (S-enantiomer) amide local anaesthetic
with a high pK a and low lipid solubility which blocks nerve fibres involved in pain …

Ropivacaine (Naropin®) is the pure S (−)-enantiomer of propivacaine, and is a long-acting
amide local anaesthetic agent, eliciting nerve block via reversible inhibition of sodium ion …

Synopsis The enantiomerically pure (S-enantiomer) amide local anaesthetic drug
ropivacaine blocked nerve fibres responsible for transmission of pain (Aδ and fibres) more …

Ropivacaine (Naropin®, AstraZeneca) a new long-acting amide local anaesthetic agent, is a
pure S-enantiomer, with a high pKa and relatively low-lipid solubility. Since its clinical …

Ropivacaine is a long-acting amide-type local anaesthetic, released for clinical use in 1996.
In comparison with bupivacaine, ropivacaine is equally effective for subcutaneous …

Ropivacaine is a long-acting amide local anaesthetic agent and first produced as a pure
enantiomer. It produces effects similar to other local anaesthetics via reversible inhibition of …

Purpose Ropivacaïne is a new long-acting, injectable local anaesthetic currently undergoing
clinical investigation world wide. It is structurally very similar to bupivacaine, but with less …

Ropivacaine has two advantages over bupivacaine. It provides more differential block when
given epidurally, allowing for a better separation between sensory and motor block. This …

The current study was initiated to evaluate the epidural anesthetic properties of 0.5%,
0.75%, and 1.0% ropivacaine, a new local anesthetic agent structurally similar to …

Anaesthetically equipotent doses of lidocaine, bupivacaine and a new bupivacaine–like
local anaesthetic agent, ropivacaine, were injected into the left anterior descending coronary …